Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease
15 juil. 2024 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
10 juil. 2024 07h30 HE
|
Longeveron
Longeveron® Announces U.S. FDA Grants Lomecel-B(TM) Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
Diadem Appoints Michael Rasche as Chief Executive Officer
10 juil. 2024 07h00 HE
|
Diadem SpA
Industry veteran Michael Rasche named CEO of Diadem, a leader in developing blood tests for the early prediction of progression to Alzheimer’s disease.
Neha Motwani Elected to Longeveron® Board of Directors
09 juil. 2024 09h00 HE
|
Longeveron
Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
08 juil. 2024 09h00 HE
|
Longeveron
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
Pacific Software Inc. Obtaining Quotes for the Manufacturing Cycle for Scientifically Tested Medical Food Cocktail Focused on Memory Health
28 juin 2024 18h43 HE
|
Pacific Software Inc.
Pacific Software Inc. expands into memory health with SuppleMEM AD™ and A.L.Z. Defense™. USA and Mexico distribution is planned for Q3 2024.
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
17 juin 2024 09h00 HE
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
10 juin 2024 09h00 HE
|
Longeveron
Longeveron to Present at the Emerging Growth Virtual Conference
Longeveron® Announces Contract Development and Manufacturing Business and First Contract
03 juin 2024 09h00 HE
|
Longeveron
Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms.
Longeveron® to Attend BIO International Convention 2024
28 mai 2024 08h05 HE
|
Longeveron
Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.